In The News

In Law360, Shanghai Attorneys Examine China FDA Reform Encouraging Drug and Device Innovation

Practices: Life Sciences, China Life Sciences, Intellectual Property Transactions

Life sciences partner Katherine Wang and intellectual property transactions international associate Silvia Mo (both of Shanghai) authored a Nov. 15 Law360 article that examines the China Food and Drug Administration’s (CFDA) final regulatory reform policy that encourages life sciences innovation in China.

The authors explain how the CFDA policies reflect the Chinese government’s unprecedented determination to accelerate drug and device approvals while deregulating the conduct of clinical research studies.

Cookie Settings